PRAME Polyclonal antibody

PRAME Polyclonal Antibody for WB, IP, IHC, ELISA

Host / Isotype

Rabbit / IgG







Cat no : 11438-1-AP


MAPE, OIP 4, OIP4, Opa interacting protein 4, PRAME

Tested Applications

Positive WB detected inK-562 cells
Positive IP detected inK-562 cells
Positive IHC detected inhuman lung cancer tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

Western Blot (WB)WB : 1:500-1:1000
Immunoprecipitation (IP)IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
Immunohistochemistry (IHC)IHC : 1:50-1:500
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

11438-1-AP targets PRAME in WB, IP, IHC, ELISA applications and shows reactivity with human samples.

Tested Reactivity human
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen PRAME fusion protein Ag1906
Full Name preferentially expressed antigen in melanoma
Calculated Molecular Weight 509 aa, 58 kDa
Observed Molecular Weight 50-58 kDa
GenBank Accession NumberBC014074
Gene Symbol PRAME
Gene ID (NCBI) 23532
Conjugate Unconjugated
Form Liquid
Purification MethodAntigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

The PRAME (preferentially expressed antigen of melanoma) gene was previously shown to be overexpressed in ovarian/primary peritoneal serous carcinoma compared with malignant mesothelioma using gene expression arrays. It is considered a melanocyte differentiation antigen which is overexpressed in both solid and hematologic tumors. In normal tissue, a very low level of PRAME expression is found in normal testis, adrenals, ovary and endometrium. A high level of PRAME expression has been reported for several solid tumors, including ovarian cancer, breast cancer, lung cancer and melanomas, medulloblastoma, sarcomas, head and neck cancers, neuroblastoma, renal cancer, and Wilms'tumor. As a nuclear transcriptional repressor protein, PRAME binds to retinoic acid receptor a, thereby inhibiting retinoic acid induced differentiation, growth arrest, and apoptosis.


Product Specific Protocols
WB protocol for PRAME antibody 11438-1-APDownload protocol
IHC protocol for PRAME antibody 11438-1-APDownload protocol
IP protocol for PRAME antibody 11438-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols